Johnson & Johnson (JNJ)

$271.11 +8.74 (3.33%)
Market Cap 627.42B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 24.13
Forward PE 22.57
Profit Margin 28.46%
Debt to Equity Ratio 0.44
Volume 7,837,998
Avg Vol 8,163,460
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 81%
Beta 0.24
Analysts Strong Sell
Price Target $275.42

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
parcha
parcha Aug. 18 at 10:03 PM
$VHT $XLV $LLY $JNJ Health care, biotech stocks climb to all-time highs Tuesday Health care and biotechnology stocks climbed to all-time highs Tuesday as investors searched for pockets of strength in the market beyond tech. The $44 billion State Street Health Care Select Sector SPDR ETF, made up of 62 stocks, reached a record. The fund’s total return over the past three months, including reinvested dividends, is 15.6% versus 4.8% for the S&P 500. The fund consists of 62 stocks, with Eli Lilly and Johnson & Johnson comprising 26% of the portfolio. The $19 billion Vanguard Health Care Index Fund also rose to a record, bringing its three-month total return to 16.6%. The fund contains 415 stocks and Lilly and J&J take up 22.2% of the total. https://www.cnbc.com/2026/08/17/stock-market-today-live-updates.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
parcha
parcha Aug. 18 at 10:00 PM
$JNJ Shares of Johnson & Johnson rose more than 3% in afternoon trading Tuesday, heading for a fresh closing record. If that move higher holds through the close, it would mark the stock’s first record close since July 7, when it gained 3.1% to $267.24. The stock has gained roughly 31% year to date, more than double the S&P 500′s advance in the same period.
0 · Reply
Ryuk
Ryuk Aug. 18 at 8:19 PM
$JNJ $260 by Friday. Trash. 💩
0 · Reply
kiwiSurfer
kiwiSurfer Aug. 18 at 7:48 PM
$LEGN $LEGN and $JNJ showing Bullish Massive Options Flow could it finally be happening?!!!
1 · Reply
HydrogenH2
HydrogenH2 Aug. 18 at 7:25 PM
$JNJ Enjoy the $$$ But don't forget that insiders are starting to trade it this month !! They know more about the value about the company than most "pumpers" on stocktwits !! lol
0 · Reply
PittsburghTrader
PittsburghTrader Aug. 18 at 7:13 PM
$MRK $JNJ up strong today, why no luv for $MRK ?
0 · Reply
heikoscreens
heikoscreens Aug. 18 at 5:55 PM
These are the current Dividend Aristocrats: $BDX $DOV $EMR $GWW $JNJ ...
1 · Reply
TechniTraderEducation
TechniTraderEducation Aug. 18 at 5:52 PM
Swing traders, this distinction can keep you from reacting to the wrong signal in $JNJ. When price declines on small candlesticks and falling volume, it may be a Void of Buyers—not panic selling. That tells you sellers are not necessarily taking control. How can you use this? • Avoid treating every price decline as bearish. • Check volume and Accumulation/Distribution for actual selling pressure. • Wait for evidence that buyers are returning before entering. • Recognize when corporate stock buybacks—not retail momentum—may be supporting price. These patterns are not automatic trade signals. They help you understand WHO is moving the stock so you can make a better swing-trading decision. See the patterns on the daily $JNJ stock chart: https://www.tradingview.com/chart/JNJ/K9SWWraO-Void-of-Buyers-vs-Corporate-Buyback-Patterns/ Trade wisely, Martha Stokes, CMT #SwingTrading #TechnicalAnalysis
0 · Reply
StageAnalysis
StageAnalysis Aug. 18 at 4:18 PM
Pharmaceuticals industry group is one of the strongest parts of the market currently Largest stocks in the group by weighting: $LLY, $JNJ, $MRK, $PFE, BMY, NVO, AZN, ZTS, NVS, AXSM, GSK, JAZZ, TEVA, RPRX, VTRS, SNY, ELAN, LQDA, DFTX, CORT, RHHBY, ELVN, TARS, NKTR, TAK, AMLX, SUPN, TRVI, RDY, PRGO, AMRX, OGN, PBH, HRMY, HROW, ANIP, OCUL, BHC, SEPN, INVA, MAZE, XERS, RAPP, LBRX, PAHC, CHGCY, GTBIF, MKKGY, TLX, HCM
1 · Reply
StockBraker
StockBraker Aug. 18 at 4:02 PM
$JNJ Don’t change that channel. 📺 👀
0 · Reply
Latest News on JNJ
Expert explains why healthcare is a top-performing sector

Aug 13, 2026, 11:15 PM EDT - 4 days ago

Expert explains why healthcare is a top-performing sector

ABBV AMGN BIIB GILD LLY MRK UNH

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Aug 10, 2026, 4:27 PM EDT - 8 days ago

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Jim Cramer highlights 5 investing themes — and the stocks to buy for each

Aug 6, 2026, 6:23 PM EDT - 12 days ago

Jim Cramer highlights 5 investing themes — and the stocks to buy for each

AMAT AXP COF CRWD GS KLAC LLY

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

Aug 4, 2026, 4:05 PM EDT - 14 days ago

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Aug 4, 2026, 8:45 AM EDT - 14 days ago

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Johnson & Johnson Transcript: Investor update

Aug 3, 2026, 8:00 AM EDT - 15 days ago

Johnson & Johnson Transcript: Investor update

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Aug 2, 2026, 8:00 AM EDT - 16 days ago

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Jul 30, 2026, 8:30 AM EDT - 19 days ago

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Jul 29, 2026, 6:13 PM EDT - 20 days ago

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Jul 29, 2026, 5:42 PM EDT - 20 days ago

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Johnson & Johnson lowers 2026 profit forecast

Jul 29, 2026, 5:38 PM EDT - 20 days ago

Johnson & Johnson lowers 2026 profit forecast

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Jul 29, 2026, 5:28 PM EDT - 20 days ago

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Explainer: Can J&J finally put the talc litigation behind it?

Jul 29, 2026, 12:01 PM EDT - 20 days ago

Explainer: Can J&J finally put the talc litigation behind it?

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Jul 28, 2026, 4:31 PM EDT - 21 days ago

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Jul 28, 2026, 12:26 PM EDT - 21 days ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

Jul 28, 2026, 1:03 AM EDT - 21 days ago

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

J&J offers $5.5bn to settle baby powder lawsuits

Jul 28, 2026, 12:31 AM EDT - 21 days ago

J&J offers $5.5bn to settle baby powder lawsuits

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Jul 27, 2026, 9:29 PM EDT - 21 days ago

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Jul 27, 2026, 6:47 PM EDT - 22 days ago

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Jul 27, 2026, 6:31 PM EDT - 22 days ago

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

Jul 27, 2026, 5:45 AM EDT - 22 days ago

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

NEM WMT

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Jul 23, 2026, 8:30 AM EDT - 26 days ago

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

Jul 22, 2026, 4:33 PM EDT - 27 days ago

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Jul 22, 2026, 7:21 AM EDT - 27 days ago

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jul 22, 2026, 7:00 AM EDT - 27 days ago

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jim Cramer says this old-school investing concept still wins — even in the AI boom

Jul 21, 2026, 6:30 PM EDT - 4 weeks ago

Jim Cramer says this old-school investing concept still wins — even in the AI boom

BNY CVS GS MMM WFC

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

Jul 16, 2026, 8:11 AM EDT - 4 weeks ago

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

DePuy Synthes Acquires Expanding Innovations™

Jul 16, 2026, 8:00 AM EDT - 4 weeks ago

DePuy Synthes Acquires Expanding Innovations™

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Jul 15, 2026, 12:09 PM EDT - 4 weeks ago

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 4 weeks ago

Johnson & Johnson Earnings Call Transcript: Q2 2026

Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 4 weeks ago

Johnson & Johnson Slides: Q2 2026

Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 4 weeks ago

Johnson & Johnson Earnings release: Q2 2026

Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 4 weeks ago

Johnson & Johnson Quarterly report: Q2 2026

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

Jul 15, 2026, 7:27 AM EDT - 4 weeks ago

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

ASML INTC

Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:35 AM EDT - 4 weeks ago

Johnson & Johnson Hikes Guidance, Stock Falls

Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:33 AM EDT - 4 weeks ago

Johnson & Johnson Bumps Up Guidance as Sales Rise

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Jul 15, 2026, 6:25 AM EDT - 4 weeks ago

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Jul 15, 2026, 6:23 AM EDT - 4 weeks ago

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 15, 2026, 6:20 AM EDT - 4 weeks ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

The Big 3: UNH, KO, JNJ

Jul 9, 2026, 1:00 PM EDT - 5 weeks ago

The Big 3: UNH, KO, JNJ

KO UNH

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jul 8, 2026, 7:45 AM EDT - 5 weeks ago

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jim Cramer says these are the 5 stocks to buy during this market rotation

Jul 6, 2026, 6:29 PM EDT - 6 weeks ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 7 weeks ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Jun 26, 2026, 12:35 PM EDT - 7 weeks ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 25, 2026, 5:00 AM EDT - 7 weeks ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

Jun 15, 2026, 6:00 AM EDT - 2 months ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 6:41 AM EDT - 2 months ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 13, 2026, 6:33 AM EDT - 2 months ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 7:45 AM EDT - 2 months ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Jun 11, 2026, 2:03 AM EDT - 2 months ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Jun 10, 2026, 11:22 AM EDT - 2 months ago

Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Jun 10, 2026, 6:20 AM EDT - 2 months ago

Johnson & Johnson CEO Says Cure for Certain Cancers Is Realistic Goal

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:00 AM EDT - 2 months ago

Johnson & Johnson Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

Jun 9, 2026, 9:20 AM EDT - 2 months ago

Trouble Ahead For GLP-1 Drugs As Health Plans Stop Paying

AMGN LLY MRK NVO PFE

Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 2 months ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion

parcha
parcha Aug. 18 at 10:03 PM
$VHT $XLV $LLY $JNJ Health care, biotech stocks climb to all-time highs Tuesday Health care and biotechnology stocks climbed to all-time highs Tuesday as investors searched for pockets of strength in the market beyond tech. The $44 billion State Street Health Care Select Sector SPDR ETF, made up of 62 stocks, reached a record. The fund’s total return over the past three months, including reinvested dividends, is 15.6% versus 4.8% for the S&P 500. The fund consists of 62 stocks, with Eli Lilly and Johnson & Johnson comprising 26% of the portfolio. The $19 billion Vanguard Health Care Index Fund also rose to a record, bringing its three-month total return to 16.6%. The fund contains 415 stocks and Lilly and J&J take up 22.2% of the total. https://www.cnbc.com/2026/08/17/stock-market-today-live-updates.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
parcha
parcha Aug. 18 at 10:00 PM
$JNJ Shares of Johnson & Johnson rose more than 3% in afternoon trading Tuesday, heading for a fresh closing record. If that move higher holds through the close, it would mark the stock’s first record close since July 7, when it gained 3.1% to $267.24. The stock has gained roughly 31% year to date, more than double the S&P 500′s advance in the same period.
0 · Reply
Ryuk
Ryuk Aug. 18 at 8:19 PM
$JNJ $260 by Friday. Trash. 💩
0 · Reply
kiwiSurfer
kiwiSurfer Aug. 18 at 7:48 PM
$LEGN $LEGN and $JNJ showing Bullish Massive Options Flow could it finally be happening?!!!
1 · Reply
HydrogenH2
HydrogenH2 Aug. 18 at 7:25 PM
$JNJ Enjoy the $$$ But don't forget that insiders are starting to trade it this month !! They know more about the value about the company than most "pumpers" on stocktwits !! lol
0 · Reply
PittsburghTrader
PittsburghTrader Aug. 18 at 7:13 PM
$MRK $JNJ up strong today, why no luv for $MRK ?
0 · Reply
heikoscreens
heikoscreens Aug. 18 at 5:55 PM
These are the current Dividend Aristocrats: $BDX $DOV $EMR $GWW $JNJ ...
1 · Reply
TechniTraderEducation
TechniTraderEducation Aug. 18 at 5:52 PM
Swing traders, this distinction can keep you from reacting to the wrong signal in $JNJ. When price declines on small candlesticks and falling volume, it may be a Void of Buyers—not panic selling. That tells you sellers are not necessarily taking control. How can you use this? • Avoid treating every price decline as bearish. • Check volume and Accumulation/Distribution for actual selling pressure. • Wait for evidence that buyers are returning before entering. • Recognize when corporate stock buybacks—not retail momentum—may be supporting price. These patterns are not automatic trade signals. They help you understand WHO is moving the stock so you can make a better swing-trading decision. See the patterns on the daily $JNJ stock chart: https://www.tradingview.com/chart/JNJ/K9SWWraO-Void-of-Buyers-vs-Corporate-Buyback-Patterns/ Trade wisely, Martha Stokes, CMT #SwingTrading #TechnicalAnalysis
0 · Reply
StageAnalysis
StageAnalysis Aug. 18 at 4:18 PM
Pharmaceuticals industry group is one of the strongest parts of the market currently Largest stocks in the group by weighting: $LLY, $JNJ, $MRK, $PFE, BMY, NVO, AZN, ZTS, NVS, AXSM, GSK, JAZZ, TEVA, RPRX, VTRS, SNY, ELAN, LQDA, DFTX, CORT, RHHBY, ELVN, TARS, NKTR, TAK, AMLX, SUPN, TRVI, RDY, PRGO, AMRX, OGN, PBH, HRMY, HROW, ANIP, OCUL, BHC, SEPN, INVA, MAZE, XERS, RAPP, LBRX, PAHC, CHGCY, GTBIF, MKKGY, TLX, HCM
1 · Reply
StockBraker
StockBraker Aug. 18 at 4:02 PM
$JNJ Don’t change that channel. 📺 👀
0 · Reply
HydrogenH2
HydrogenH2 Aug. 18 at 3:50 PM
$JNJ $AMGN $LLY and talking about Cramer ... "Cramer i'm not going to say that on tv !! " https://youtu.be/8DJlogbrDcA?t=74
0 · Reply
HydrogenH2
HydrogenH2 Aug. 18 at 3:46 PM
$JNJ $AMGN $LLY First Cantor Fitzgerald is this guy's family !! and always do opposite of Cramer's calls... here why... lol https://www.youtube.com/shorts/JTSl9Q38Ih0
0 · Reply
HydrogenH2
HydrogenH2 Aug. 18 at 3:43 PM
$JNJ
0 · Reply
HydrogenH2
HydrogenH2 Aug. 18 at 3:15 PM
$JNJ $ABBV I'm taking profits !! Thanks !!
0 · Reply
GettnFibbywIT
GettnFibbywIT Aug. 18 at 3:14 PM
$JNJ $XLV
0 · Reply
LiveTradePro
LiveTradePro Aug. 18 at 2:35 PM
$JNJ Patience paying off https://share.trendspider.com/chart/JNJ/6682yrl8al
0 · Reply
GordoHLYK13
GordoHLYK13 Aug. 18 at 2:11 PM
$IGC $MRNA $PFE $ABB $JNJ
1 · Reply
parcha
parcha Aug. 18 at 1:31 PM
Jim Cramer's top 10 things to watch in the stock market Tuesday $AMGN $LLY $JNJ Cantor Fitzgerald and Mizuho both raised their price targets on Amgen, while keeping hold ratings on the stock. Cantor said the big question is whether Amgen’s late-stage pipeline can deliver the positive updates needed to keep the stock’s momentum going. We own Eli Lilly and Johnson & Johnson for the Club, with both seeing some encouraging prescription trends for new drugs in the first week of August. https://www.cnbc.com/2026/08/18/jim-cramers-top-10-things-to-watch-in-the-stock-market-tuesday.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
Parlandoconme
Parlandoconme Aug. 18 at 10:17 AM
$TOMZ Buy now (Low) and sell later (High). This advice is only for Ray the day trader who has the opposite philosophy. $STE $AZN $JNJ $PEP
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Aug. 18 at 1:14 AM
$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low. Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 17 at 10:13 PM
$JNJ
0 · Reply
DidYouReadThis
DidYouReadThis Aug. 17 at 10:07 PM
Who do you think is most likely to make an #acquisition first between now and the #end of the #year? Any #target predictions? $ABBV $JNJ $LLY $MRK #tenderoffer #Q3? #Q4?
0 · Reply